RLMD - Latest News
Relmada Therapeutics, Inc. (RLMD), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $549.3M. Beta to the broader market is 0.43.
The article list below shows the most recent RLMD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent RLMD Headlines
Relmada Therapeutics Q1 Earnings Call Highlights
marketbeat.com - May 12, 2026
Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 1
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 12, 2026
Relmada Therapeutics, Inc.
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com - May 12, 2026
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-ri
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
globenewswire.com - May 6, 2026
CORAL GABLES, Fla. , May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc.
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
globenewswire.com - May 5, 2026
CORAL GABLES, Fla. , May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc.
How News Affects RLMD Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RLMD's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked RLMD news questions
- What is the latest RLMD news headline?
- The most recent RLMD headline (May 12, 2026) is "Relmada Therapeutics Q1 Earnings Call Highlights". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the RLMD news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What RLMD news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual RLMD options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.